Cantor Fitzgerald raised the price target for the ProQR Therapeutics N.V. (NASDAQ:PRQR) stock from “a Neutral” to “an Overweight”. The rating was released on December 22, 2022, according to finviz. We previously noted in another research note published on February 14, 2022 by Citigroup that downgraded the stock from a Buy to a Neutral with a price target of $1.70 for PRQR stock. The research report from Stifel has downgraded the stock from Buy to Hold, with a price target set at $3. In their research brief published February 01, 2022, Raymond James analysts initiated the ProQR Therapeutics N.V. stock to Strong Buy with a price target of $19.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of ProQR Therapeutics N.V. (NASDAQ:PRQR) raised 3.55% to close Thursday’s market session at $3.21, higher as compared to yesterday’s close. The stock price fluctuated between $2.965 and $3.24 throughout the trading session with the volume trading being 983131 shares, which represented a significant variation when compared to the three months average volume of 2.84 million shares. The firm’s stock price fluctuated 0.94% within the last five trades and 10.69% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 310.91% in the last 6 months and 86.63% was added to its value over the previous 3 months. PRQR stock is trading at a margin of 6.91%, 5.53% and 111.55% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
As of the close of trading, PRQR deals in the Healthcare domain. The stock is trading -15.08 percent below its 52-week high and 505.66 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 91.2. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does ProQR Therapeutics N.V.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $255.00 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 60.71 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 3.34, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 20.89 percent of ProQR Therapeutics N.V. shares are owned by insiders, and 42.20 percent are held by financial institutions.